Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Non-cash Items (2023 - 2025)

Contineum Therapeutics' Non-cash Items history spans 3 years, with the latest figure at $2.7 million for Q3 2025.

  • Quarterly Non-cash Items fell 92.95% to $2.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Sep 2025, down 92.95% year-over-year, with the annual reading at $2.1 million for FY2024, 85.8% down from the prior year.
  • Non-cash Items came in at $2.7 million for Q3 2025, down from $2.9 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $39.0 million in Q3 2024 to a low of $2.0 million in Q1 2024.
  • The 3-year median for Non-cash Items is $4.4 million (2025), against an average of $12.8 million.
  • The largest YoY upside for Non-cash Items was 192.68% in 2025 against a maximum downside of 92.95% in 2025.
  • Contineum Therapeutics' Non-cash Items stood at $14.9 million in 2023, then plummeted by 85.8% to $2.1 million in 2024, then skyrocketed by 30.01% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTNM's Non-cash Items are $2.7 million (Q3 2025), $2.9 million (Q2 2025), and $5.9 million (Q1 2025).